IM Cannabis Corp. Common Shares (IMCC)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable advantages, conservative balance sheets, and a margin of safety. IM Cannabis fails most of those tests. It imports, distributes, and sells medical cannabis in Israel and Germany, a scale business with regulatory and commodity pressures. In the most recent quarter shown, fiscal Q1 2026, revenue was $8.7 million, net income was -$2.3 million, and the net margin was -26.24%. The provided growth figures show revenue down 0.23% and profit down 295.99%, so the trend is not stabilization but deterioration. FairStock's calculations from the 2026-10-13 close show a negative P/E of -0.02, ROCE of -18.57%, Piotroski F-Score of 3/9, and an Altman Z-Score of -16.56, which is a severe distress signal. The market cap is only $1.9 million. Trailing free cash flow is $49,000, a 2.6% FCF yield, but that is tiny and does not offset a quarterly loss of $2.3 million. The company pays no dividend and has a beta of 2.21, so the shares are volatile; the 52-week range of $0.09 to $8.65 shows the market's uncertainty. There is no Peter Lynch category because there are only 0 years of filed results, not the 3 needed. A FairStock Score of 20/100 reinforces the weak picture. I see no meaningful moat, no demonstrated earning power, and no margin of safety at $1.36. This is a speculative micro-cap, not a Graham-style bargain.

In plain English: IM Cannabis sells medical cannabis in Israel and Germany. In the latest quarter shown, fiscal Q1 2026, revenue was $8.7 million but it lost $2.3 million, and sales and profits have been shrinking. At $1.36, the price does not look cheap against those weak results and the company's $1.9 million market value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer